Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07439653Phase 1Not Yet Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Role: lead

NCT05103683Phase 1Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Role: lead

NCT05156866Phase 1Active Not Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Role: lead

NCT07322094Phase 1Recruiting

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Role: lead

NCT06690775Phase 2Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Role: lead

NCT05948826Phase 1Active Not Recruiting

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Role: lead

NCT06005740Phase 1Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Role: lead

NCT05159440Phase 1Active Not Recruiting

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Role: lead

All 8 trials loaded